GlassScriptPhysician profile
Jeanne P Lipscomb
NPI 1790748515
$9,507.01
in general payments reported to CMS, 2019-2025
32 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $799 · 2021: $1,872 · 2022: $1,417 · 2023: $1,130 · 2024: $1,209 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,948.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,012.10 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,270.50 | 2019-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $1,255.27 | 2019-2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $1,227.21 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Mylan Specialty L.P. | $502.18 | 2019-2023 | Yupelri |
| Insmed, INC. | $444.25 | 2019-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $418.66 | 2020-2024 | Acthar |
| Genzyme Corporation | $382.15 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $287.04 | 2020-2025 | Glassia |
| Philips North America LLC | $283.89 | 2019-2025 | Vest Therapy Und |
| Ani Pharmaceuticals, INC. | $214.60 | 2023-2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $170.31 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $150.74 | 2019 | |
| Genentech USA, INC. | $112.83 | 2019-2022 | |
| Amgen INC. | $87.26 | 2021-2023 | Tezspire |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $68.85 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $62.41 | 2019-2024 | |
| Harmony Biosciences LLC | $62.29 | 2021-2023 | Wakix |
| United Therapeutics Corporation | $61.97 | 2023-2024 | Tyvaso |
| Baxter Healthcare | $61.64 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Pulmonx Corporation | $55.42 | 2021-2022 | |
| Circassia INC. | $48.93 | 2019-2020 | |
| Inogen, INC. | $46.51 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $42.63 | 2021 | |
| Merck Sharp & Dohme LLC | $39.08 | 2022-2023 | |
| Shire North American Group INC | $36.06 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $25.42 | 2019 | |
| Apria Healthcare LLC | $18.36 | 2021 | |
| Astellas Pharma US INC | $15.73 | 2022 | |
| Advanced Respiratory, INC | $14.96 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.56 | 2023 | Nuzyra |
| Resmed Corp | $13.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanne Lipscomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.